Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1964 1
1965 26
1966 52
1967 40
1968 63
1969 46
1970 46
1971 62
1972 47
1973 50
1974 52
1975 63
1976 63
1977 66
1978 91
1979 102
1980 93
1981 118
1982 150
1983 162
1984 181
1985 186
1986 231
1987 207
1988 200
1989 210
1990 272
1991 234
1992 280
1993 273
1994 315
1995 349
1996 370
1997 375
1998 361
1999 417
2000 446
2001 515
2002 550
2003 624
2004 763
2005 871
2006 952
2007 899
2008 938
2009 1035
2010 1255
2011 1342
2012 1413
2013 1437
2014 1644
2015 1919
2016 1871
2017 1996
2018 2175
2019 2324
2020 3046
2021 3494
2022 3925
2023 3791
2024 2131

Search Results

42,444 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.
Garassino MC, Gadgeel S, Speranza G, Felip E, Esteban E, Dómine M, Hochmair MJ, Powell SF, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Kurata T, Gray JE, Schwarzenberger P, Jensen E, Pietanza MC, Rodríguez-Abreu D. Garassino MC, et al. J Clin Oncol. 2023 Apr 10;41(11):1992-1998. doi: 10.1200/JCO.22.01989. Epub 2023 Feb 21. J Clin Oncol. 2023. PMID: 36809080 Free PMC article. Clinical Trial.
Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options.
Petrella F, Rizzo S, Attili I, Passaro A, Zilli T, Martucci F, Bonomo L, Del Grande F, Casiraghi M, De Marinis F, Spaggiari L. Petrella F, et al. Curr Oncol. 2023 Mar 7;30(3):3160-3175. doi: 10.3390/curroncol30030239. Curr Oncol. 2023. PMID: 36975452 Free PMC article. Review.
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study.
de Castro G Jr, Kudaba I, Wu YL, Lopes G, Kowalski DM, Turna HZ, Caglevic C, Zhang L, Karaszewska B, Laktionov KK, Srimuninnimit V, Bondarenko I, Kubota K, Mukherjee R, Lin J, Souza F, Mok TSK, Cho BC. de Castro G Jr, et al. J Clin Oncol. 2023 Apr 10;41(11):1986-1991. doi: 10.1200/JCO.21.02885. Epub 2022 Oct 28. J Clin Oncol. 2023. PMID: 36306479 Free PMC article. Clinical Trial.
Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade.
Pai JA, Hellmann MD, Sauter JL, Mattar M, Rizvi H, Woo HJ, Shah N, Nguyen EM, Uddin FZ, Quintanal-Villalonga A, Chan JM, Manoj P, Allaj V, Baine MK, Bhanot UK, Jain M, Linkov I, Meng F, Brown D, Chaft JE, Plodkowski AJ, Gigoux M, Won HH, Sen T, Wells DK, Donoghue MTA, de Stanchina E, Wolchok JD, Loomis B, Merghoub T, Rudin CM, Chow A, Satpathy AT. Pai JA, et al. Cancer Cell. 2023 Apr 10;41(4):776-790.e7. doi: 10.1016/j.ccell.2023.03.009. Epub 2023 Mar 30. Cancer Cell. 2023. PMID: 37001526 Free PMC article.
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.
Lee SM, Schulz C, Prabhash K, Kowalski D, Szczesna A, Han B, Rittmeyer A, Talbot T, Vicente D, Califano R, Cortinovis D, Le AT, Huang D, Liu G, Cappuzzo F, Reyes Contreras J, Reck M, Palmero R, Mak MP, Hu Y, Morris S, Höglander E, Connors M, Biggane AM, Vollan HK, Peters S. Lee SM, et al. Lancet. 2023 Aug 5;402(10400):451-463. doi: 10.1016/S0140-6736(23)00774-2. Epub 2023 Jul 6. Lancet. 2023. PMID: 37423228 Clinical Trial.
42,444 results
You have reached the last available page of results. Please see the User Guide for more information.